B. Braun and Philips join forces to innovate in ultrasound-guided regional anesthesia and vascular access
April 03 2017 - 8:00AM
B. Braun Melsungen AG, the global leader in regional anesthesia and
pain management, and Royal Philips (NYSE:PHG) (AEX:PHIA), a global
leader in ultrasound and image guided therapy solutions, today
announced a multi-year strategic alliance to innovate
ultrasound-guided regional anesthesia – a rapidly growing
alternative to general anesthesia – and vascular access. Leveraging
the companies’ combined deep clinical expertise and R&D
capabilities, as well as sales and service channels, B. Braun and
Philips are jointly developing and commercializing solutions to
support anesthesiologists and hospitals in critical areas of
regional anesthesia. These solutions are intended to enhance needle
visualization and guidance, as well as optimize procedure workflow
and resource planning. The alliance will also focus on vascular
access procedures, such as those used to insert catheters into
deeply seated veins as part of a catheter-based treatment.
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/0159c62d-b9f4-4a46-ab78-e986f06f31bf
http://www.globenewswire.com/NewsRoom/AttachmentNg/896b98f9-c71e-430a-9549-e4e2f1f3c97a
http://www.globenewswire.com/NewsRoom/AttachmentNg/b4194af0-65b2-4b90-9811-541f2c0ce232
As a platform on which to implement their joint innovations,
Philips and B. Braun are launching the new Xperius ultrasound
system, which will be available in a cart and ultra-mobile tablet
version. Based on the input of clinical experts, Xperius was
specifically designed to support the needs in regional anesthesia
at the point of care. The system offers an intuitive user interface
and exceptional image quality for confident needle targeting and
positioning, as well as ergonomic features such as the articulating
arm.
Xperius complements B. Braun´s innovative offering in the field
of ultrasound guided regional anesthesia which includes the newly
launched peripheral nerve block portfolio comprising Stimuplex®
Ultra 360® and Contiplex® Ultra 360®. It has also been specifically
designed to support future innovations for needle visualization and
guidance. The two companies will offer education, training, service
and support that will enable anesthesiologists and healthcare
providers to extract maximum benefit from the system.
Regional anesthesia or analgesia involves the injection of an
anesthetic in the proximity of a nerve, targeting areas of a
patient’s body that are subject to surgical intervention. Regional
anesthesia can have significant advantages over general anesthesia
for both patients and hospitals. Patients undergoing regional
anesthesia typically benefit from reduced opioid consumption and
fewer side-effects, such as nausea. Moreover, regional anesthesia
may lead to faster post-surgical recovery, allowing patients to
ambulate or leave the hospital sooner, which benefits both patients
and hospitals.
However, regional anesthesia and especially peripheral nerve
blocks are not easy to perform. Maximizing anesthetic effectiveness
and preventing damage to the targeted nerve or other tissue
structures depends on the accurate placement of the needle tip
through which the anesthetic will be injected or a catheter will be
placed. Hence, there is a real need for innovations that
continually improve the safety, effectiveness, and efficiency of
regional anesthesia procedures.
“Our customers are looking for fully integrated system solutions
that address all aspects of their everyday work in caring for
patients, including the enhanced efficiency needed to meet
ever-increasing demand for their services,” said Dr. Meinrad Lugan,
Member of the Board for the Hospital Care Division at B. Braun.
“This new alliance with Philips illustrates our commitment to
sharing expertise, not only with our customers, but also with other
key technology players, to meet healthcare needs and challenges
faced today and into the future.”
“Philips and B. Braun have a worldwide reputation for clinical
innovations and a shared commitment to work with patients and care
providers to optimize healthcare delivery and improve patient
outcomes,” said Rob Cascella, Chief Business Leader of the
Diagnosis & Treatment Businesses at Philips. “By partnering
with B. Braun, we have created a solution for ultrasound-guided
regional anesthesia comprising the Xperius ultrasound system,
decision support software, echogenic needles, and a suite of
services. We look forward to jointly developing further
innovations. This new alliance is a great example of our commitment
to partnering with industry leaders with complementary skills to
increase our footprint in the therapy market.”
The Xperius platform will be co-branded and sold via B. Braun’s
global sales network, with Philips providing installation and
service.
* Xperius is a registered trademark of B. Braun and Philips
About Royal PhilipsRoyal Philips (NYSE:PHG)
(AEX:PHIA) is a leading health technology company focused on
improving people’s health and enabling better outcomes across
the health continuum from healthy living and
prevention, to diagnosis, treatment and home care. Philips
leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions.
Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as
in consumer health and home care. Philips’ health
technology portfolio generated 2016 sales of EUR 17.4 billion and
employs approximately 71,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
About B.BraunB. Braun is one of the world's
leading manufacturers of medical devices and pharmaceutical
products and services. With over 58,000 employees in 64 countries,
B. Braun develops high quality product systems and services for
users around the world. In 2016, the Group generated sales of
approximately EUR 6.5 billion. Every service provided by B. Braun
incorporates its entire expertise and the company's deep
understanding of users' needs. In developing its products, product
systems and services, B. Braun acts like a sparring partner. A
companion who promotes developments through constructive dialog and
the motivation to improve things. With its constantly growing
portfolio of effective medical care solutions, B. Braun makes a
substantial contribution towards protecting and improving people's
health. News about B. Braun can be found here: www.bbraun.com.
For further information, please contact:
Steve Klink
Philips Group Press Office
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com
Fabienne van der Feer
Philips Image Guided Therapy
Tel.: + 31 6 22698001
E-mail: fabienne.van.der.feer@philips.com
Franziska Hentschke
B. Braun Corporate Communications
Tel.: + 49 5661 71- 1635
E-mail: franziska.hentschke@bbraun.com
Constance Walker
B. Braun Medical Inc. Marketing Communications
Tel.: 610-997-4216
E-mail: connie.walker@bbraun.com
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Apr 2023 to Apr 2024